crofelemer
MYTESI (crofelemer) is (camp)-stimulated cystic fibrosis transmembrane conductance regulator (cftr) chloride ion (cl¯) channel, and the calcium-activated cl¯ channels (cacc) at the luminal membrane of enterocytes. First approved in 2012.
Drug data last refreshed 52m ago · AI intelligence enriched 1mo ago
MYTESI (crofelemer) is an oral antidiarrheal small molecule approved in 2012 that reduces secretory diarrhea by blocking chloride and water secretion in the intestinal epithelium. It acts on cAMP-stimulated CFTR chloride channels and calcium-activated chloride channels at the enterocyte luminal membrane. The drug normalizes fluid flow in the gastrointestinal tract by inhibiting excess chloride and water loss.
Product is in peak commercial phase with modest Part D adoption; team focus is on maintaining market position in a niche indication with limited growth.
(cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (Cl¯) channel, and the calcium-activated Cl¯ channels (CaCC) at the luminal membrane of enterocytes. The CFTR Cl¯ channel and CaCC regulate Cl¯ and fluid secretion by intestinal epithelial cells. Crofelemer…
Antidiarrheal
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moMYTESI offers stable career opportunities in a niche therapeutic area with minimal competitive distractions, ideal for professionals seeking deep market expertise in a focused patient population. However, limited clinical activity and small absolute sales ($7M Part D) mean this is a specialty portfolio brand with constrained team size and career growth potential.